Immune checkpoint blockade shows promise but faces resistance challenges in nasopharyngeal carcinoma
Immune checkpoint blockade may help treat nasopharyngeal carcinoma
This narrative review examines immune checkpoint blockade in nasopharyngeal carcinoma. It highlights that while 5-year overall survival for …
A narrative review suggests immune checkpoint blockade could guide new treatments for nasopharyngeal carcinoma, though resistance remains a …
Review of epigenetic dysregulation in nasopharyngeal carcinoma management
Epigenetic changes could guide better treatment plans for nasopharyngeal cancer patients soon
This narrative review examines epigenetic dysregulation, including aberrant DNA and RNA methylation, histone modifications, and non-coding R…
A new review explains how silent chemical switches control cancer spread and how doctors might use them to tailor treatments for patients.
Comprehensive salivary gland–sparing helical tomotherapy reduces radiation-induced xerostomia in nasopharyngeal carcinoma patients
New radiation technique spares saliva glands in throat cancer
This prospective cohort study evaluated 266 patients with nasopharyngeal carcinoma treated with comprehensive salivary gland–sparing helical…
A precise radiation method cut severe dry mouth to 0.4% in nasopharyngeal cancer patients, while keeping survival high.
EBNA1 SeroStrip-HT shows high accuracy for nasopharyngeal carcinoma risk assessment in a nested case-control study
A Blood Test May Spot a Rare Cancer Years Before Symptoms Appear
This nested case-control study evaluated the EBNA1 SeroStrip-HT in prospective cohorts from Singapore and Shanghai, China.
A simple blood test can spot a rare throat cancer up to four years before symptoms appear, giving doctors time to treat it early.
Meta-analysis of 7,750 saliva samples validates non-invasive disease prediction models for nasopharyngeal carcinoma, colorectal cancer, and PLHIV
Spit Test Could Predict Multiple Diseases
This meta-analysis reviewed public 16S saliva data from 22 cohorts involving 7,750 samples to assess multi-disease prediction models.
A simple spit test might soon predict multiple diseases at once, offering a non-invasive way to check for serious health conditions without …
Mini review examines genetic polymorphisms and viral markers linked to nasopharyngeal carcinoma risk
What genes and viruses really drive this rare throat cancer risk?
This mini review synthesizes evidence regarding genetic polymorphisms and viral markers associated with nasopharyngeal carcinoma susceptibil…
A rare throat cancer is driven by specific gene changes and the Epstein-Barr virus, while common HPV links remain unproven for this disease.
Intravenous vitamin C did not reduce gastrointestinal toxicities but attenuated platelet decline in nasopharyngeal carcinoma patients
Intravenous vitamin C may help protect platelets during cancer treatment in Thailand
A randomized, double-blind, placebo-controlled trial in Thailand assessed 2 g of intravenous vitamin C prior to chemotherapy in patients wit…
Intravenous vitamin C helped slow platelet loss in Thai cancer patients undergoing treatment, though it did not reduce common side effects l…
Penpulimab plus chemotherapy significantly improved progression-free survival in recurrent or metastatic nasopharyngeal carcinoma
New drug plus chemo delays cancer growth in advanced nasopharyngeal cases
This randomized, double-blind phase 3 trial evaluated penpulimab combined with cisplatin/carboplatin and gemcitabine versus placebo plus che…
Adding penpulimab to chemotherapy delays cancer growth by nearly three months in advanced nasopharyngeal cases, offering new hope for patien…
Anti-PD-1 plus chemoradiotherapy improved event-free survival in MS1 subtype nasopharyngeal carcinoma patients compared with chemoradiotherapy alone
New Test Picks Who Wins From Cancer Drug
This review analyzed pooled data from two Phase III randomized clinical trials involving 407 patients with locoregionally advanced nasophary…
A new test identifies which nasopharyngeal cancer patients will survive longer when adding immunotherapy to standard radiation and chemother…
Becotatug vedotin shows antitumor activity in pretreated recurrent or metastatic nasopharyngeal carcinoma
A New Drug Shows Promise for Tough-to-Treat Nasopharyngeal Cancer
A phase IIa single-arm trial of 61 patients with platinum-refractory recurrent or metastatic nasopharyngeal carcinoma found an objective res…
For patients with a hard-to-treat head and neck cancer who have few treatments left, a new experimental therapy is showing encouraging resul…
MRLN sparing radiotherapy shows non-inferior survival, reduced toxicity in nasopharyngeal carcinoma
New Radiation Plan Saves Swallowing Power
A phase 3 RCT of 568 adults with untreated, non-metastatic nasopharyngeal carcinoma found MRLN sparing radiotherapy was non-inferior to stan…
A new radiation plan for throat cancer lets patients skip a specific area, helping them keep their swallowing strength and eat normally for …
Meta-analysis finds Qi-deficiency constitution most prevalent in nasopharyngeal carcinoma health states
Study finds link between Chinese medicine body types and nasopharyngeal cancer
A meta-analysis of 11 studies including 1,174 patients across nasopharyngeal carcinoma (NPC) health states found Qi-deficiency constitution …
A new analysis of 1,174 patients shows that a 'Qi-deficiency' body type is linked to Epstein-Barr virus infection and nasopharyngeal cancer.
Questions about Nasopharyngeal Carcinoma
Can saliva samples help predict if I have nasopharyngeal carcinoma or other cancers?
Yes, saliva samples can help predict nasopharyngeal carcinoma (NPC) risk by detecting EBV markers and microbial changes, but they are not yet standard for other cancers.
Full answer →Did taking intravenous vitamin C help reduce stomach problems during chemotherapy for nasopharyngeal carcinoma?
No, intravenous vitamin C did not reduce stomach problems during chemotherapy for nasopharyngeal carcinoma in a clinical trial.
Full answer →What viral markers are linked to a higher risk of getting nasopharyngeal carcinoma?
Antibodies to Epstein-Barr virus (EBV) proteins, especially EBNA1, and circulating EBV DNA are linked to higher NPC risk.
Full answer →Does helical tomotherapy reduce dry mouth side effects in nasopharyngeal carcinoma patients?
Yes, helical tomotherapy (a form of IMRT) significantly reduces dry mouth (xerostomia) in nasopharyngeal carcinoma patients by sparing salivary glands, with low rates of severe xerostomia.
Full answer →Can a specific saliva test accurately predict my risk for nasopharyngeal carcinoma?
Yes, a specific saliva test measuring IgA antibodies to EBNA1 protein can accurately predict NPC risk, with sensitivity up to 90% and specificity over 91%.
Full answer →All Nasopharyngeal Carcinoma Articles
- Immune checkpoint blockade shows promise but faces resistance challenges in nasopharyngeal carcinoma
- Review of epigenetic dysregulation in nasopharyngeal carcinoma management
- Comprehensive salivary gland–sparing helical tomotherapy reduces radiation-induced xerostomia in nasopharyngeal carcinoma patients
- EBNA1 SeroStrip-HT shows high accuracy for nasopharyngeal carcinoma risk assessment in a nested case-control study
- Meta-analysis of 7,750 saliva samples validates non-invasive disease prediction models for nasopharyngeal carcinoma, colorectal cancer, and PLHIV
- Mini review examines genetic polymorphisms and viral markers linked to nasopharyngeal carcinoma risk
- Intravenous vitamin C did not reduce gastrointestinal toxicities but attenuated platelet decline in nasopharyngeal carcinoma patients
- Penpulimab plus chemotherapy significantly improved progression-free survival in recurrent or metastatic nasopharyngeal carcinoma
- Anti-PD-1 plus chemoradiotherapy improved event-free survival in MS1 subtype nasopharyngeal carcinoma patients compared with chemoradiotherapy alone
- Becotatug vedotin shows antitumor activity in pretreated recurrent or metastatic nasopharyngeal carcinoma
- MRLN sparing radiotherapy shows non-inferior survival, reduced toxicity in nasopharyngeal carcinoma
- Meta-analysis finds Qi-deficiency constitution most prevalent in nasopharyngeal carcinoma health states
- Meta-analysis: PD-1/PD-L1 inhibitors show 45% ORR, 16.27-month median OS in recurrent/metastatic NPC